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A subset of individuals infected with HIV-1 develops
broadly neutralizing antibodies (bNAbs) that can
prevent infection, but it has not yet been possible
to elicit these antibodies by immunization. To sys-
tematically explore how immunization might be
tailored to produce them, we generated mice ex-
pressing the predicted germline or mature heavy
chains of a potent bNAb to the CD4 binding site
(CD4bs) on the HIV-1 envelope glycoprotein (Env).
Immunogens specifically designed to activate B cells
bearing germline antibodies are required to initiate
immune responses, but they do not elicit bNAbs.
In contrast, native-like Env trimers fail to activate B
cells expressing germline antibodies but elicit bNAbs
by selecting for a restricted group of light chains
bearing specific somatic mutations that enhance
neutralizing activity. The data suggest that vaccina-
tion to elicit anti-HIV-1 antibodies will require immu-
nization with a succession of related immunogens.INTRODUCTION
A fraction of HIV-1-infected individuals develop potent broadly
neutralizing antibodies (bNAbs) that target several independent
sites on gp160, the viral envelope glycoprotein (Env) (West
et al., 2014). When passively transferred into non-human pri-
mates or into genetically engineered or humanized mice, theseantibodies can protect against challenge with chimeric simian/
human immunodeficiency virus (SHIV) or HIV-1 viruses, respec-
tively (Burton et al., 2012; Klein et al., 2013;Mascola andHaynes,
2013; West et al., 2014). Antibodies were also the only correlate
of protection in a recent phase 3 human HIV-1 vaccine trial that
showed limited efficacy (Karasavvas et al., 2012; Rerks-Ngarm
et al., 2009). Thus, one of the goals of the HIV-1 vaccine effort
has been to elicit bNAbs by immunization. However, this goal
has not been achieved despite more than 25 years of concerted
vaccination efforts.
Why it is so difficult to elicit these antibodies was only fully
appreciated after the advent of single-cell antibody cloning tech-
niques (Klein et al., 2013; West et al., 2014). Antibody cloning re-
vealed that anti-HIV-1 antibodies are unusual in that they carry
large numbers of somatic hypermutations that are required for
binding to most recombinant HIV-1 Env antigens and for broad
neutralization (Mouquet et al., 2010; Scheid et al., 2011; Wu
et al., 2010). Thesemutations are likely to arise as a result of mul-
tiple rounds of hypermutation and selection in the germinal cen-
ter in response to rapidly evolving escape mutations in the HIV-1
Env (Mouquet et al., 2010; Scheid et al., 2009). This idea is sup-
ported by the observation that bNAbs co-evolve with HIV-1 in the
host through multiple rounds of HIV-1 escape from antibody
pressure (Doria-Rose et al., 2014; Klein et al., 2013; Liao et al.,
2013; Wu et al., 2015). Considered together, these findings
have led to the hypothesis that eliciting such antibodies may
require using a series of engineered or naturally arising antigens
to direct the antibody response (Dimitrov, 2010; Doria-Rose
et al., 2014; Jardine et al., 2013; Klein et al., 2013; Liao et al.,
2013; Wu et al., 2011). According to this idea, an antigen that
activates B cells carrying a germline antibody would initially beCell 161, 1505–1515, June 18, 2015 ª2015 Elsevier Inc. 1505
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Figure 1. Characterization of B Cells in GLVH and MuVH Mice
(A) Representative FACS plots show binding of eOD-GT8 and eOD-GT8
CD4bs knockout (KO) proteins by mature naive B cells in naive wild-type
C57Bl6 (WT), GLVH, and MuVH mice.
(B) Graph shows frequency of eOD-GT8-binding B cells in naive WT, GLVH,
and MuVH mice. Each dot represents one mouse. Lines indicate mean of the
group.
(C) Pie charts show heavy- (HC) and light-chain (LC) sequences cloned from
purified single-cell sorted B cells from naive mice. The number in the center of
the pie chart is the number of sequences analyzed, each colored slice repre-
sents one clone (identical V gene andCDRL3), and its size is proportional to the
size of the clone. White indicates unique sequences.
(D) CDRL3 aa lengths from LCs in (C).
See also Figure S1.used to expand a reactive B cell clone and produce a group of
somatic variants by hypermutation. To shepherd the antibody
response toward broad neutralization, the initial immunization
would be followed by one or a series of related antigens.1506 Cell 161, 1505–1515, June 18, 2015 ª2015 Elsevier Inc.To test this hypothesis, we produced immunoglobulin (Ig)
heavy-chain knockin mice expressing the predicted germline
(GLVH) or mature mutated (MuVH) version of 3BNC60, a bNAb
that targets the CD4 binding site (CD4bs) of HIV-1 (Scheid
et al., 2011). 3BNC60 is one of a closely related group of potent
antibodies referred to as VRC01-class antibodies (West et al.,
2012), arising in several different individuals, all of which are
derived from IgHV1-2*02 (West et al., 2014). In addition to the
shared origin of their heavy chains, this group of antibodies all
carry light chains that have short (five amino acid [aa]) third
complementarity determining regions (CDR3s) (West et al.,
2012; Zhou et al., 2013).
Mice that carry heavy-chain knockin genes have a restricted B
cell repertoire because the heavy chain is fixed. Nevertheless,
the repertoire remains relatively diverse because the antibody
light chain is produced by random VJ recombination in devel-
oping B cells. Thus, only a small fraction of the B cells carry
heavy and light chains that combine to produce antibodies
able to bind to the HIV-1 Env (see below). Immunization of
GLVH mice affords the opportunity to evaluate antigens for their
ability to select B cells expressing light chains that show features
that could support bNAb evolution. In contrast, MuVH mice
represent a synthetic intermediate because the human heavy
chain carries all of the required mutations, but the mouse light
chain is germline.
To track the evolution of the HIV-1 antibody response in GLVH
and MuVH mice, we immunized them with antigens designed to
bind to the predicted unmutated precursor of 3BNC60 or with
BG505 SOSIP trimers that resemble the native HIV-1 Env.
RESULTS
3BNC60 Knockin Mice
GLVH and MuVH mice were produced by gene targeting using
C57Bl-6 embryonic stem cells (Pelanda et al., 1997; Shih et al.,
2002) (Figure S1A). GLVH reverts all of the heavy chain residues
outside of CDRH3 (Hoot et al., 2013) to germline. CDRH3 cannot
be reverted with certainty because the sequence represents the
combined effects of random V(D)J recombination, N addition,
deletion, and somaticmutation. Both strains showed near-normal
frequencies of immature and recirculating B cells in the BM (Fig-
ure S1B) and of mature B cell populations in spleen (Figure S1C).
To determine the frequency of naive B cells that bind to Env-
based antigens in the knockin mice, we stained splenocytes
with an improved version (eOD-GT8) of the previously described
immunogen eOD-GT6, an engineered outer domain of gp120 de-
signed to bind to both germline and mature versions of 3BNC60
and other VRC01-class antibodies (see below and Jardine et al.,
2013; Jardine et al., 2015). The average number of naive B cells
that bind to eOD-GT8 in GLVH and MuVH mice (0.08% and
0.13%, respectively) was similar to that found in wild-type
C57Bl6mice (0.05%), indicating that thesecells are rareand found
at frequencies similar to those in wild-type C57Bl6 mice (Figures
1A and 1B). To examine the antibody repertoire in naive B cells
in these mice, we isolated single cells by flow cytometry and
sequenced their Ig genes. As expected, the heavy chain was al-
ways the product of the respective knockin allele, and the mouse
light-chain sequences were less diverse than in wild-type C57Bl6
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Figure 2. Antibody Responses to Immunization by GLVH Mice
(A) Graphs show ELISA results of serum (1/900 dilution) for individual mice against eOD-GT8 (blue) and eOD-GT8 CD4bs knockout (KO, red) from wild-type
C57Bl6 (WT) and GLVH mice. Naive serum (0) and serum after one, two, or three (1, 2 or 3) immunizations with eOD-GT8 60-mer.
(B) Graphs show ELISA results of serum (1/900 dilution) for individual mice against 426c.TM4DV1-3 (blue) or 426c.TM4DV1-3 CD4bs knockout (KO, red) fromwild-
type C57Bl6 (WT) and GLVH mice. Naive serum (0) and serum after one (1) immunization with multimerized 426c.TM4DV1-3.
(C) Graphs show ELISA results of serum (1/300 dilution) for individual mice against BG505 SOSIP and YU2gp140-F in naive mice (0) or after three (3) immuni-
zations with eOD-GT8 60-mer.
(D) Heavy- (HC) and light-chain (LC) sequences from single antigen-binding B cells isolated from four eOD-GT8 60-mer-immunized GLVH mice. Pie charts as in
Figure 1A. A clone is defined by identical V gene and similar CDRL3.
(E) CDRL3 aa lengths from LCs in (D).
(F) Graph shows ELISA results for monoclonal antibodies (5 mg/ml) cloned from eOD-GT8 60-mer-immunized GLVH mice against eOD-GT8 (blue) and eOD-GT8
CD4bs knockout (KO, red).
(G) Graphs show ELISA results of serum (1/300 dilution) for individual mice against BG505 SOSIP or YU2 SOSIP in wild-type C57Bl6 (WT) and GLVH mice after
immunization with BG505 SOSIP or YU2 SOSIP, respectively. Naive serum (0) and serum after two (2) or three (3) immunizations.
For ELISA graphs, lines indicate mean of the group, and the colors of the lines correlate to the colors of the dots. See also Figures S2 and S3 and Table S1.B cells (51/59, 24/44, and 33/63 unique sequences for wild-type
C57Bl6, GLVH, and MuVH, respectively) (Figure 1C). Consistent
with the rare occurrence of antigen-binding cells in the naive
knockin mice (Figures 1A and 1B), none of the mouse light chains
showed the five-residue CDRL3 signature typical of authentic
3BNC60 or of other VRC01-class antibodies (Figure 1D).
Immune Responses in 3BNC60 GLVH Knockin Mice
Like most other potent bNAbs, reversion of the somatic muta-
tions in the 3BNC60 antibody to the predicted germline antibody
results in complete loss of affinity and neutralizing activity for all
recombinant HIV-1 Env proteins and viruses tested (Hoot et al.,
2013; Jardine et al., 2013; McGuire et al., 2013; Mouquet et al.,
2010; Scheid et al., 2011; Xiao et al., 2009) (Figures S2A and
S2B). Todeterminewhether naiveGLVHBcells canbe stimulatedwith antigens that are specifically engineered to activate cells
expressing germline VRC01-class antibodies (Figure S2C), we
immunized these mice and wild-type C57Bl6 controls with
eOD-GT8 60-mer orwithmultimerized 426c.TM4DV1-3 (McGuire
et al., 2014; Experimental Procedures). Immunization produced a
robust antibody response inwild-type C57Bl6 andGLVHmice af-
ter one or two immunizations (Figures 2A, 2B, andS3A, andS3B).
Although the responsewas not restricted to the CD4bs, as deter-
mined by ELISA, sera from the eOD-GT8 60-mer-immunized
mice showed some preference for the wild-type versus a control
eOD-GT8 CD4bs knockout protein (Figures 2A and S3A). Finally,
none of the sera from the eOD-GT8 60-mer-immunized mice
showed cross-reactivity to a native-like BG505 SOSIP (Julien
et al., 2013; Sanders et al., 2013) or a YU2 gp140 foldon trimer
(YU2 gp140-F) (Yang et al., 2002) (Figures 2C and S3C).Cell 161, 1505–1515, June 18, 2015 ª2015 Elsevier Inc. 1507
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Figure 3. Antibody Responses to Immunization by MuVH Mice
(A) Graphs show ELISA results of serum (1/300 dilution) for individual mice
against eOD-GT8 (blue) and eOD-GT8 CD4bs knockout (KO, red), 2cc core,
and YU2 gp140-F. Naive serum (0) and serum after three (3) immunizations
with eOD-GT8 60-mer.
(B) As in (A) but after BG505 SOSIP-immunization. ELISA against BG505
SOSIP, 2cc core, and YU2 gp140-F (blue) and YU2 gp140-F CD4bs knockout
(KO, red). Lines indicate mean of the group and the colors of the lines correlate
to the colors of the dots.
(C) Neutralizing activity in TZM-bl assays of serum from individual naive, eOD-
GT8 60-mer- or BG505 SOSIP-immunized mice (M) against a panel of HIV-1
viruses. Numbers indicate the reciprocal dilution of serum at the median
inhibitory concentration (IC50): red, >1,000; orange, 100–1000; yellow, 50–100,
and white, not neutralized at any dilution tested. Gray indicates background
activities against the control MuLV virus.
See also Figure S4.eOD-GT8-binding IgG+ B cells are rare in GLVH naive mice but
increase to 5.8% on average after immunization (Figure S3D). A
fraction of these cells appeared to express CD4bs-specific anti-
bodies as measured by flow cytometry (Figure S3E). To further1508 Cell 161, 1505–1515, June 18, 2015 ª2015 Elsevier Inc.characterize the B cell responses to eOD-GT8 60-mer in GLVH
mice, we sorted single cells that bound to eOD-GT8, but not
eOD-GT8 CD4bs knockout, and cloned their antibody genes
(Figure S3E). 71 light- and 55 heavy-chain sequences were ob-
tained from 4 mice. As expected, all of the heavy chains were
GLVH. The 71 antibodies include 8 clones ranging in size from
2 to 13 clonal members, one of which appeared in more than
one mouse. In addition, there were 13 cells that carried unique
sequences (Figures 2D and S3F and Table S1A). The CDRL3
lengths of the light chains showed a near-normal distribution
when compared to naive GLVH or control wild-type C57Bl6
mice, with only one of the expanded clones showing the five-res-
idue CDRL3 signature typical of 3BNC60 and related antibodies
(Figures 2E and S3G and Table S1A).
Out of 20 antibodies cloned fromB cells expressing antibodies
that bound to eOD-GT8 but not eOD-GT8 CD4bs knockout
by FACS, 7 were CD4bs specific as measured by ELISA (Fig-
ure 2F). However, none of the 17 monoclonal antibodies tested
neutralized any of the tier 1 and 2 viruses tested (Table S1B).
We conclude that the eOD-GT8 60-mer, an antigen designed
to activate B cells expressing germline 3BNC60 antibody and
select only for early somatic mutations, elicits B cell responses
in mice that carry germline knockin antibody heavy chains,
including B cells expressing antibody light chains with five-resi-
due CDRL3s, but these antibodies do not neutralize HIV-1.
To determine whether GLVH B cells can respond to a more
native-appearing HIV-1 antigen in vivo, we immunized these
mice and wild-type C57Bl6 mice with BG505 SOSIP (Julien
et al., 2013; Sanders et al., 2013) or YU2 SOSIP. Wild-type
C57Bl6 mice developed detectable antibody responses as
measured by ELISA. In contrast, GLVH mice failed to respond
to these antigens (Figures 2G and S3H). We conclude that naive
B cells expressing GLVH paired with a heterogeneous group of
mouse light chains fail to mount significant immune responses
to BG505 SOSIP or YU2 SOSIP.
Immune Responses in 3BNC60 MuVH Knockin Mice
Serum from naiveMuVHmice has no detectable HIV-1 Env-bind-
ing activity in ELISA or neutralizing activity in TZM-bl assays (Fig-
ures 3A–3C, and S4A, and S4B). To determine whether anti-HIV-
1 antibodies can be elicited in these mice, they were immunized
three times, with eOD-GT8 60-mer or BG505 SOSIP. The eOD-
GT8 60-mer immunization produced strong serologic responses
in MuVHmice, but the sera were not cross-reactive against other
HIV-1 proteins such as 2cc-core (an engineered gp120 [Dey
et al., 2009]) or YU2 gp140-F, and a fraction of the mice showed
CD4bs specificity as measured by ELISA on eOD-GT8 and eOD-
GT8 CD4bs knockout (Figures 3A and S4A). MuVH mice also
developed strong serologic responses to BG505 SOSIP, but in
contrast to eOD-GT8 immunization, there was serologic cross-
reactivity to 2cc core, as well as YU2 gp140-F. Moreover, a sig-
nificant fraction of the response was CD4bs specific as deter-
mined by ELISA against YU2 gp140-F and a YU2 gp140-F
CD4bs knockout mutant protein (Figures 3B and S4B).
To determine whether MuVH mice develop HIV-1 neutralizing
responses, we assayed mouse serum on a panel of nine HIV-1
viruses (eight tier 2, and one tier 1) in TZMbl-assays (Li et al.,
2005). We found that the eOD-GT8 60-mer-immunized MuVH
mice only showed modest levels of activity mainly against tier
2 Clade D (T247-23) and A (62357.14.D3.3489) viruses that
lack glycosylation at position 276 (Genbank: ACD63071 and
ABY50658.1, respectively) (Figure 3C). In contrast, all seven
out of ten BG505 SOSIP-immunized MuVH mice that showed a
robust response to BG505 SOSIP in ELISA developed strong
neutralizing responses against the autologous Clade A virus. In
addition, high levels of neutralization were also evident against
T247-23 and 62357.14.D3.3489, and more modest levels of
neutralization were seen against three other clade A tier 2
viruses. Finally, four of the seven also showed a low level of
neutralizing activity against the clade B tier 2 strain YU2.DG
(Figure 3C). Thus, BG505 SOSIP trimers elicit potent responses
with some cross-clade breadth in MuVH mice, but eOD-GT8
60-mer does not.
eOD-GT8-binding IgG+ B cells cannot be detected in naive
MuVH mice but increase to 15% and 30% after immunization
with eOD-GT8 60-mer or BG505 SOSIP, respectively (Fig-
ure S4C). Thus, both antigens were able to induce clonal expan-
sion and antigen-specific memory B cells. To characterize the
antibodies that develop in the MuVH mice, we isolated and
cloned the antibodies from antigen-specific memory B cells (Fig-
ures S4D and S4E).
As expected, all of the heavy chains obtained carried theMuVH
knockin sequence. A total of 138 and 269 light chains were
cloned from mice immunized with eOD-GT8 60-mer and
BG505 SOSIP, respectively (Figure 4A and Tables S2 and S4).
The antibodies obtained from eOD-GT8 60-mer-immunized
mice represent 15 independent clones ranging in size from 2 to
24 members; 4 of the clones appeared independently in both
eOD-GT8 60-mer-immunized mice. In addition, there were 13
cells that carried unique sequences (Figure 4A and Table S2).
In contrast to the antibodies obtained from eOD-GT8 60-mer-
immunized GLVH mice, the light chains from MuVH immunized
mice were highly biased to express 5 aa residue CDRL3s. More-
over, the fourth residue in the CDRL3 was highly selected for an
E, which is an important residue in the 3BNC60 antibody and
other VRC01 class antibodies. It forms a contact with the back-
bone of the V5 loop of HIV-1 Env (Scheid et al., 2011; Wu et al.,
2010; Zhou et al., 2013) (Figures 4A and 4B and Table S2). When
assayed by ELISA, the majority of these antibodies were CD4bs
specific to eOD-GT8, and a fraction was cross-reactive to YU2
gp140-F (Figure 4C). However, despite CD4bs specificity, only
two viruses (T247-2 and 62357.14.D3.3489, which lack glycosyl-
ation at aa position 276) were neutralized by the monoclonal an-
tibodies tested (Figure 4D and Table S3). Thus, eOD-GT8 60-mer
immunization of MuVH mice is highly selective for a subset of
mouse light chains with short CDRL3s that allow binding to the
CD4bs of eOD-GT8, but this is not sufficient to produce broad
neutralizing activity against tier 2 viruses.
Antibodies cloned from BG505 SOSIP-immunized MuVH mice
were far more clonally restricted than those obtained after eOD-
GT8 60-mer immunization. Light chains were cloned from 269
cells from 3 separate mice, and again, in all cases analyzed,
the heavy chain was from the knockin. In contrast to eOD-GT8
60-mer, BG505 SOSIP immunization was dominated by only
six highly expanded clones, one of which arose independently
in all three mice (Figure 4A and Table S4). Similar to eOD-GT860-mer immunization, the B cell clones expanded by BG505
SOSIP immunization were highly biased to express light chains
with 5 aa residue CDRL3s that carry the E at the fourth position
of CDRL3 (Figures 4A and 4B and Table S4). When tested by
ELISA, all but 4 of the 20 antibodies elicited by BG505 SOSIP
were CD4bs specific on eOD-GT8, and a fraction of these
were cross-reactive to YU2 gp140-F (Figure 4E). Finally, some
of these monoclonal antibodies showed neutralizing activity
against several tier 2 viruses (Figure 4D and Table S5). We
conclude that, in contrast to eOD-GT8-, BG505 SOSIP immuni-
zation elicits neutralizing antibodies against a diverse group of
tier 2 viruses in MuVH mice.
Somatic Mutations
Only the antibodies arising from BG505 SOSIP immunization
neutralized tier 2 viruses with an intact glycosylation site at
position 276 (Figure 4D and Tables S3 and S5). To gain further
insights into this phenomenon, we analyzed the monoclonal
antibodies and somatic mutations that arose during the
immunization.
The total number of light-chain mutations arising as a result
of immunization by the eOD-GT8 60-mer or BG505 SOSIP was
similar in both strains of mice, irrespective of whether the
knockin heavy chain was germline or mature (Figure 5A). In addi-
tion, both immunogens selected for B cells bearing the same VL
germline gene (VL10-94*01) carrying similar number of somatic
mutations and nearly identical CDRL3s in MuVH mice (Figures
4A and 5B and Tables S2 and S4). Thus, the nature of the immu-
nogen did not influence the rate of somatic mutations in the light
chains.
However, some mutations in VL10-94*01-expressing B cells
appeared to be specifically selected by immunization with
BG505SOSIPbecause theywere over-represented (FigureS5A).
For example, Q90Hwas found in the second position of CDRL3 of
nearly all members of the VL10-94 clone obtained independently
from three MuVH mice immunized with BG505 SOSIP but rarely
in the VL10-94 clone that arose after immunization with eOD-GT8
60-mer (Figures 4A and S5A and Tables S2 and S4,), whereas
others such as the E mutation found in the fourth residue of
CDRL3 were selected by both immunogens (Figure 4A and
Tables S2 and S4). Thus, immunization with BG505 SOSIP and
eOD-GT8 60-mer led to differential selection of somatically
mutated light chains.
To determine whether light chain mutations might be respon-
sible for increasing neutralizing activity after BG505 SOSIP im-
munization, we produced an antibody that carries the MuVH
and the predicted germline light chain of VL10-94*01 (GL in
Figure 5C and Tables S3 and S5). When this antibody was
compared to BG505 SOSIP-derived monoclonal antibodies,
the reverted antibody showed only modest activity. The reverted
antibody was similar to the eOD-GT8 60-mer-derived VL10-
94*01 monoclonal antibodies, indicating that only BG505 SOSIP
immunization selects for light-chain somatic mutations that in-
crease neutralizing antibody activity in MuVH mice (Figure 5C).
Moreover, the Q90H found in the CDRL3 of nearly all VL10-94-ex-
pressing clones derived from BG505 SOSIP-immunized MuVH
mice was sufficient to increase neutralizing activity (Figures 5C
and 5D and Tables S3 and S5). Additional mutations that furtherCell 161, 1505–1515, June 18, 2015 ª2015 Elsevier Inc. 1509
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Figure 4. Monoclonal Antibodies from
Immunized MuVH Mice
(A) Pie charts show heavy- (HC) and light-chain
(LC) sequences cloned from two eODGT8 60-mer-
immunized (M#7 and 9) and three BG505 SOSIP-
immunized (M#16, 17, and 18) MuVHmice. VL gene
usage and CDRL3 sequences are shown for each
clone; colors correspond to colors in pie charts.
The same color indicates clones shared by
different mice. A clone is defined by identical V
gene and similar CDRL3.
(B) CDRL3 aa lengths of the LCs in (A).
(C) Graphs show ELISA results for individual
monoclonal antibodies with the indicated CDRL3s
cloned from eOD-GT8 60-mer-immunized MuVH
mice against eOD-GT8 (blue) and eOD-GT8 CD4bs
knockout (KO, red) (at 0.55 mg/ml) or against YU2
gp140-F (at 5 mg/ml).
(D) Neutralizing activity of a set of representa-
tive eOD-GT8 60-mer- or BG505 SOSIP-elicited
monoclonal antibodies against 7 HIV-1 tier 2 viruses
(1 =MuLV control, 2 = BG505/T 332N, 3 = T247-23,
4 = 62357.14.D3.3489, 5 = Q842.d12, 6 =
3365.V2.c30, 7 = YU2.DG, and 8 = 0815.v3.c3)
compared to the serum of the mouse they were
cloned from. Colors for monoclonal antibodies
indicate concentration of monoclonal antibody at
the median inhibitory concentration (IC50): orange,
0.1 to 1 mg/ml; yellow, 1 to 10 mg/ml; green, 10–25 or
50 mg/ml and white, not neutralized at any concen-
tration tested. Lowest dilution tested for serum was
1:50, highest concentration tested for monoclonal
antibodies were between 10 and 50 mg/ml (see
Tables S3 and S5). X indicates sample not tested.
The numbering of the antibodies corresponds to the
numbering of the antibodies in Tables S3 and S5.
Colors and numbering for serum as in Figure 3C.
(E) Graphs show ELISA results for individual
monoclonal antibodies with the indicated CDRL3s
cloned from BG505 SOSIP-immunized MuVH mice
against eOD-GT8 (blue) and eOD-GT8 CD4bs
knockout (KO, red) (at 0.55 mg/ml) or against YU2
gp140-F (at 5 mg/ml).
For ELISA graphs, lines indicate mean of the
group, and the colors of the lines correlate to the
colors of the dots. See also Figure S4 and Tables
S2, S3, S4, and S5.enhanced or interfered with neutralizing activity appeared
randomly (Figure 5C). Finally, there was no evidence for selection
of specific mutations in the heavy chain in MuVH B cells, as seen
by the absence of significant clonal expansion of any particular
mutation (Figure S5B).
In contrast to the light chains, mutations in the knockin VDJH
sequence were significantly higher in GLVH than in MuVH B cells
(Figures 5E and S5B), even when comparing Peyer’s Patch
germinal center B cells in unimmunized mice that are not re-1510 Cell 161, 1505–1515, June 18, 2015 ª2015 Elsevier Inc.sponding to injected antigens (Figure 5F).
However, the mutation rate in the germ-
line intron downstream of JH4, which is
contiguous to the VDJH, was similar in
the two mouse strains (Figure 5G). We
conclude that the somatic mutation
machinery is equally active in the twoknockin B cell types, but the highly mutated MuVH is less sus-
ceptible to mutation than its unmutated GLVH counterpart.
DISCUSSION
Immunoglobulin knockinmice such asGLVH andMuVH provide a
unique opportunity to examine the effects of specific immuno-
gens and trace the evolution of an anti-HIV-1 antibody starting
from predicted germline or from a synthetic intermediate
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Figure 5. Somatic Mutations in Immunized
Mice
(A) Graph shows number of light-chain (LC) so-
matic hypermutations in individual sequences
obtained after eOD-GT8 60-mer or BG505 SOSIP
immunization in GLVH or MuVH mice.
(B) LC somatic hypermutations in VL10-94*01 in
individual sequences obtained after eOD-GT8
60-mer or BG505 SOSIP immunization in MuVH
mice.
(C) VL10-94*01 germline (GL) and 17 monoclonal
antibodies from immunized MuVH mice sorted by
neutralization strength. Neutralization data for each
antibody tested against virus 1 = T247-23, 2 =
62357.14.D3.3489, 3 = BG505/T332N, 4 =
3365.v2.c30, 5 = YU2.DG, 6 = 0815.v3.c3, 7 =
HxBC2.DG, and 8 = MuLV. Colors for monoclonal
antibodies indicate concentration of monoclonal
antibody at the median inhibitory concentration
(IC50): red, <0.1 mg/ml; orange, 0.1 to 1 mg/ml; yel-
low, 1 to 10 mg/ml; green, 10–25 or 50 mg/ml and
white, not neutralized at anyconcentration tested. X
indicates sample not tested (see also TablesS3 and
S5).Positionof aamutations in theLCscompared to
germline is highlighted in red.
(D) Graph shows neutralization score for VL10-
94*01 cloned antibodies with Q90Q or Q90H
CDRL3 from immunized MuVH mice. Neutraliza-
tion score: sum of viruses tested IC50 0.1–1 mg/ml:
3, 1–10 mg/ml: 2, 10–50 mg/ml: 1, and >50 mg/ml: 0.
(E) Somatic hypermutations in individual heavy-
chain (HC) sequences obtained after eOD-GT8
60-mer or BG505 SOSIP immunization in GLVH
or MuVH mice. Data in (A), (B), and (E) are
pooled from 9 mice (M#1, 2, 3, 4, 7, 9, 16, 17,
and 18).
(F) Somatic hypermutations in individual germinal
center B cell HC sequences obtained from naive
GLVH or MuVH mice.
(G) Somatic hypermutations in individual
germinal center B cell JH4 intron sequences
obtained from naive GLVH or MuVH mice. Data in
(F) and (G) are pooled from two independent
experiments with two to three mice each. 60–80 clones were sequenced for GLVH or MuVH germinal center B cells HC and JH4. Y axes on graphs in (A),
(B), (E), (F), and (G) indicate nucleotide mutations/1,000 bp.
Read lines in all graphs indicate the mean of the group. See also Figure S5 and Tables S3 and S5.composed of a mutated human heavy V region chain and a
mouse germline light chain. The B cells in these mice show
reduced repertoire diversity because the heavy chain is fixed;
nevertheless, the light chains are free to recombine randomly,
and the resulting B cell repertoire contains only very rare cells
that bind to the HIV-1 immunogens tested.
Immunization revealed that B cells bearing predicted germline
antibodies only responded to antigens specifically designed to
bind to these antibodies and not to more native-appearing HIV-1
Env trimers. This result is consistent with the observation that the
germline version of 3BNC60 and related antibodies fail to bind to
nearly all tested recombinant HIV-1 Env antigens and supports
the idea that specifically designedantigenswill be required toelicit
B cells bearing these antibodies (Hoot et al., 2013; Jardine et al.,
2013; McGuire et al., 2013). Nevertheless, it remains possible
that a more diverse repertoire of light chains would include a rare
pairing that might be triggered by a more native-like trimer.One of the objectives of immunization with a germline-target-
ing antigen is to expand and further diversify rare clones of B
cells that can serve as precursors of bNAbs. For 3BNC60 and
related CD4bs antibodies, this would require selection of B cells
expressing antibodies with short CDRL3s and somatic hypermu-
tation in germinal centers. Although rare in the pre-immune
repertoire, GLVH B cells expressing antibodies with short
CDRL3s were enriched after immunization with the eOD-GT8
60-mer, providing proof of concept for selection of germline pre-
cursors of this class of antibodies by germline targeting antigens.
In contrast, both the engineered eOD GT8 and the native-like
BG505 SOSIP trimer elicited antigen-specific B cell responses
in mice bearing MuVH. However, only BG505 SOSIP produced
a significant neutralizing response.
Both types of antigens selected rare MuVH B cells expressing
light chains with short CDRL3s and both induced similar levels of
somatic hypermutation. It would be interesting to determineCell 161, 1505–1515, June 18, 2015 ª2015 Elsevier Inc. 1511
whether these cells would also be selectedwhen competing with
a complete repertoire of B cells in a wild-type C57Bl6 mouse.
Nevertheless, the responses to the immunogens differed in two
important ways, each of which likely contributed to the eventual
selection of tier 2 neutralizing antibodies to HIV-1 by the BG505
SOSIP trimer. First, the repertoire of light chains that was
selected to undergo clonal expansion by the trimer was far
more restricted than for the eOD-GT8 60-mer. This restriction is
likely to be related to the glycan at position 276 that enforces
the relatively narrow geometry of the recessed CD4 binding
pocket in the trimer (Julien et al., 2013; Kwong et al., 1998; Lyum-
kis et al., 2013). Under physiologic conditions, this cavity accom-
modates the single terminal Ig-like domain in CD4. Significant al-
terations, including somatic mutations, deletions, or insertions,
must bemade for the bulkier paired heavy- and light-chain Ig do-
mains in 3BNC60 and related antibodies to access the CD4bs
(West et al., 2014). Many of these alterations are already present
in the heavy chain of MuVH B cells, facilitating extensive contacts
with gp120 (West et al., 2014). Nevertheless, the steric restric-
tions imposedby theglycan at 276 inBG505SOSIP limit thenum-
ber of different light chains that can be recruited into the immune
response against the trimer. In contrast, eOD-GT8 was designed
to be amore open structure that is missing the glycan at position
276 and can accommodate germline antibodies. It therefore re-
cruits a more diverse but overlapping set of antibodies in mice
bearing the MuVH, none of which has significant breadth against
tier 2 viruses in TZM-bl assays. Our work was limited to BG505
SOSIP as a model for a native-appearing antigen, and it remains
possible that other antigens with similar steric restrictions would
be equally efficient in selecting neutralizing antibodies.
The second difference between the two immunogens was in
their ability to select for IgVL mutations that enhance breadth
and potency. In particular, the Q90H mutation in the CDRL3 of
the VL10-94 light chains that are selected in the BG505 SOSIP
immunized mice may aid in rigidifying the light chain contacts
to the CD4bs. Structural modeling of the VL10-94 light chain in-
dicates that the histidine side chain, unlike the glutamine side
chain, can adopt a commonly observed, low-energy conforma-
tion that also makes stabilizing interactions within the light chain
(Figure S5C). The planar packing with Y91, the close proximity to
the N276 glycan, a hydrogen bond with CDRL1, and a potential
for interacting with a gp120-bridging water molecule may help
preconfigure the antibody for engagement of the CD4bs. The
modeling and neutralization data indicate that the mutation
could cause structural changes that influence binding to gp120
and may be necessary for the activity of the BG505 SOSIP
elicited antibodies (Figure S5C).
Although only a small number of the mutations are likely to be
crucial for breadth and potency, achieving the right combination
of aa substitutions by random mutagenesis is a low probability
event. Finding that the mature, fully mutated 3BNC60 VH suffers
fewer mutations after immunization than the predicted germline
3BNC60 despite equal rates of somatic mutation in the light
chains and in the JH4 intron suggests that the sequence of the
VH is an important determinant of its susceptibility to hypermuta-
tion. Consistent with this idea, the fully mutated 3BNC60 VH
has many fewer AID target sites than the predicted germline
VH (Betz et al., 1993; Longerich et al., 2006; Neuberger et al.,1512 Cell 161, 1505–1515, June 18, 2015 ª2015 Elsevier Inc.1998). RGYW/WRCY are preferred targets for somatic hypermu-
tation: 9 out of 12 RGYW and 7 out of 8 WRCY motifs found in
GLVH sequence are missing in MuVH (Figure S5D).
HIV-1 and SHIV infection can be prevented by passive infusion
of potent bNAbs into mice or macaques, but despite significant
efforts, including large clinical trials, all attempts to elicit such
antibodies in humans by immunization have failed to date (Klein
et al., 2013; Mascola and Haynes, 2013; West et al., 2014). Anti-
body cloning experiments revealed that these bNAbs differ from
most other antibodies in that they are significantly moremutated,
leading to the suggestion that eliciting themwould require immu-
nization with a sequential series of different antigens selected or
designed to shepherd the antibody response through several
successive rounds of mutation and selection in germinal centers
(Klein et al., 2013; Mouquet et al., 2010; Scheid et al., 2009).
Consistentwith this notion, elegant studies of humanHIV-1 infec-
tion showacorrelation betweenHIV-1 viral evolution and the anti-
body response (Doria-Rose et al., 2014; Liao et al., 2013; Wu
et al., 2015). Our experiments demonstrate that specific immuno-
gens are required to target B cells at different stages of evolution
of the anti-HIV-1 neutralizing response and lend support to the
idea that vaccination for HIV-1will require a strategy that involves
sequential immunization with different antigens.
EXPERIMENTAL PROCEDURES
Mice and Immunizations
Knockin mice were produced by gene targeting using the human VDJH
sequences of the mature and germline 3BNC60 heavy chain (Hoot et al.,
2013). The targeting vector was designed with homologous regions flanking
the endogenous J segments, which results in the deletion of the J segments
and thereby minimizes rearrangement of the wild-type locus (Pelanda et al.,
1997; Shih et al., 2002). Mice were immunized once every 2 weeks with
10 mg of protein in Alum Imject (Thermo Scientific). Serum was collected
2 weeks after each immunization. All experiments were performed according
to the protocols approved by the IACUC at Rockefeller University.
Protein Production
eOD-GT8 is an improved version of eOD-GT6 (Jardine et al., 2013, 2015). The
eOD-GT8 CD4bs knockout carries mutations to reintroduce the N276 glycan
and also includes D368R and N279A. eOD-GT8 60-mer for immunization
and monomers for ELISA detection were produced as previously described
(Jardine et al., 2013). The 426c.TM4DV1-3 immunogen (with or without AviTag)
is a derivative of the 426c.NLGS.TMDV1-3 (McGuire et al., 2014) with the
following additional modifications: D276N, S278R, and G471S (HXB2
numbering). The protein was produced as previously described (McGuire
et al., 2014). Multimerized 426c.TM4DV1-3 was generated as follows: Avi-
tagged and biotinylated 426c.TM4DV1-3 was mixed with streptavidin and bio-
tinylated dextran (Life Technologies) at a 3:1 ratio of Env to biotin, with the
assumption that the biotin had 77 biotin molecules/dextran. Streptavidin
(New England Biolabs) was added to achieve a 3:1:1 Env to streptavidin
to biotin ratio. To generate YU2 SOSIP.664, a gene encoding YU2 SOSIP.664
was constructed to include the ‘‘SOS’’ substitutions (A501Cgp120 and
T605Cgp41), the ‘‘IP’’ substitution (I559Pgp41), changing the gp120-gp41 cleav-
age site to 6R (REKR to RRRRRR) and introducing a stop codon after residue
664gp41 (HXB2 numbering) analogous to mutations introduced to generate
BG505 SOSIP.664 as described (Sanders et al., 2013). YU2 SOSIP.664,
BG505 SOSIP.664, and B41 SOSIP.664 (referred to as YU2 SOSIP, BG505
SOSIP, and B41 SOSIP) were produced and purified by the 2G12/SECmethod
as previously described (Chung et al., 2014; Pugach et al., 2015; Sanders et al.,
2013). YU2 gp140-F CD4bs knockout is a YU2 gp140-foldon (F) HIV-1 Envwith
A281T and D368K mutations, and proteins were produced as previously
described (Forsell et al., 2008).
ELISA
ELISA for eOD-GT8, eOD-GT8 CD4bs knock-out, YU2 gp140-F, YU2 gp140-F
knock-out, YU2 SOSIP, and B41 SOSIP was performed by coating high
binding 96-well plates (Corning Incorporated) with 200 ng/well of protein.
After incubation overnight (ON) at 4C, the plates were washed in wash buffer
(PBS with 0.05% TWEEN 20 [Sigma]) and incubated in blocking buffer (PBS
with 2% milk). Serum samples or monoclonal antibodies were added in
dilutions. Plates were washed and secondary antibody, HRP conjugated
anti-mouse or anti-human IgG (Jackson ImmunoResearch), was added. Plates
were developed by the addition of HRP substrate (Life Technologies), and
the absorbance was measured at 405 nm. ELISA specific for BG505 SOSIP
was performed using the D7324-capture ELISA as described in Sanders
et al. (2013).
TZM-bl Neutralization Assay
Serum samples and monoclonal antibodies were tested for neutralization
against a panel of selected HIV-1 pseudoviruses using a TZM-bl neutralization
assay as previously described (Li et al., 2005).
B Cell Enrichment
B cells were enriched from single-cell suspensions of total splenocytes prior to
flow cytometry staining by magnetic bead separation using anti-CD19 or anti-
CD43 MicroBeads (Miltenyi Biotec). The separation was performed on MACS
separation LS columns according to the manufacturer’s instructions.
Flow Cytometry
Single-cell suspensions of total splenocytes, enriched B cells, or BM were
stained with different combinations of the following antibodies: anti-CD4
APC-eFluor 780, anti-CD8 APC-eFluor 780, anti-Gr1 APC-eFluor 780, anti-
F4/80 APC-eFluor 780, anti-B220 APC, anti-B220 APC-eFluor 780, anti-
B220 FITC, anti-CD19 PeCy7, anti-CD38 Alexa Fluor 700, anti-CD93 APC,
anti-IgM PerCP-eFluor 710, anti-CD21/CD35 eFluor 450 and anti-GL7 eFluor
660 (eBiosciences), anti-CD23 PE (BioLegend), anti-CD4 PE-CF594, anti-
CD8 PE-CF594, anti-Ly-6G and Ly-6C PE-CF594, anti-IgG1 and CD95
BV421 (BD Biosciences). Live dead aqua stain was added to separate dead
cells (Life Technologies), and eOD-GT8-specific cells were visualized by the
addition of FITC-conjugated eOD-GT8 and PE-conjugated eOD-GT8 CD4bs
knockout. BG505 SOSIP- (Sok et al., 2014) and 2cc-specific memory B cells
were visualized by the addition of biotinylated protein with the addition of
streptavidin-conjugated PE and APC, respectively (BD Biosicences).
B Cell Sorting
Staining and single-cell sorting of naive and memory B cells was performed
as follows: for naivemice, CD4-, CD8-, Gr-1-, F4/80-, B220+, and IgM+ B cells
were sorted. For immunized mice, CD4-, CD8-, Gr-1-, F4/80-, B220+, CD38-,
IgM-, IgG+, eOD-GT8 CD4bs knockout and eOD-GT8+ or CD4-, CD8-, Gr-1-,
F4/80-, B220+, CD38-, IgM-, IgG+, BG505 SOSIP+, and 2cc+ memory B cells
were single-cell sorted into 96-well plates using a FACSAria III sorter (Becton
Dickinson). The cells were lysedwith 4 ml lysis buffer containing RNASin (Prom-
ega) 40 U/ml (0,3 ml), DPBS (Dulbecco) 103 (0.2 ml), DTT (Invitrogen) 100 mM
(0.4 ml), and nuclease-free water (3.1 ml). The sorted plates were stored at
80C until further processing (Tiller et al., 2009). Sequencing and cloning
primers are listed in Table S6. Antibodies were cloned using a modified
sequence and ligation-independent cloning (SLIC) approach as described
in Li and Elledge (2007). Antibodies were produced in HEK293-6E cells as
previously described (Klein et al., 2014). Bulk sorted GC B cells were amplified
with the following primers: pF: GGGATGGTCATGTATCATCCTTTTTCTAG
TAGC and p279: TCCTAGGAACCAACTTAAGAGT.
Structural Modeling
Tocreateastructuralmodelofoneof theantibodieselicited in theMuVHmouseby
BG505 SOSIP, we integrated information from HIV bNAb structures and mouse
light-chain structures. The antibody 3BNC117 has very high sequence similarity
to3BNC60(tenmutations inheavychainand threemutations in lightchain [Scheid
et al., 2011]) and has a co-crystal structure available (PDB: 4JPV). We made an
initial model of 3BNC60 by running 50 ROSETTA-Fixbb (Leaver-Fay et al.,
2011) simulations to model the mutations from the 3BNC117 structure. The eli-cited antibodies contain amutatedmouse light chain from the VL10-94*01 germ-
line gene; here, we focused on the Q90H mutation. To model the light chain,
we used an unrelated crystal structure of a mouse VL10-94*01 antibody (PDB:
1EMT).Wesuperimposed themouseantibody to the3BNC60model andcreated
ahybridof 3BNC60-matureheavychainandVL10-94*01 lightchain tomimicwhat
was elicited in MuVH. The 1EMT structure did not contain a five aa CDRL3, so
we aligned the light chain from 3BNC117 and grafted the five amino CDRL3
onto our model. The final model was obtained by adding an interfacial water
molecule (as found in the structurally similar VRC-CH31 light chain; PDB: 4LSP)
and by running 100 ROSETTA-Relax simulations to allow for slight movements
of the backbone.
Statistical Analysis
Statistical differences were analyzed by the Mann-Whitney test. GraphPad
Prism software was used for analysis, and data were considered significant
at *p% 0.05, **p% 0.01, and ***p% 0.001.
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